文献速递妇科生殖医学

子宫腺肌病的病理生理、诊断进展与治疗选择

Adenomyosis Pathophysiology, Diagnostic Advances, and Therapeutic Options.
PubMed 文献 · Obstet Gynecol · 2026-04-02

本文综述子宫腺肌病的病理生理、诊断进展与治疗选择,指出该病可致异常子宫出血、痛经、慢性盆腔痛及生育力低下,影像学进步使年轻患者识别增加,诊断标准尚缺共识,药物多借鉴内异症与肌瘤数据,介入与手术可缓解症状并保留子宫,但复发与生育结局未明,需疾病特异性前瞻试验与标准化诊断标准。

要点

  • 影像学进步使子宫腺肌病在年轻育龄患者中识别增加。
  • 诊断挑战在于组织学诊断缺乏共识定义。
  • 药物多借鉴内异症与肌瘤数据,介入与手术可保留子宫但结局未明。

核心结论

  • 影像学、病理共识与新型疗法正重塑子宫腺肌病管理,但需疾病特异性前瞻试验与标准化诊断标准以优化个体化保留生育力的诊疗。

研究设计与样本

  • 综述类文章,未报告系统检索范围与样本量。

主要发现

  • 子宫腺肌病是异位子宫内膜位于子宫肌层所致的异质性非恶性子宫疾病,可致异常子宫出血、痛经、慢性盆腔痛及生育力低下。
  • 发病机制涉及性激素失衡、炎症、纤维化、神经血管生成及干细胞介导机制。
  • 合并肌瘤与子宫内膜异位症常见,加重症状严重度并使管理复杂化。
  • 药物管理多外推自子宫内膜异位症与肌瘤数据,孕激素、左炔诺孕酮宫内系统、促性腺激素释放激素类似物与拮抗剂及新兴药物疗效不一。
  • 介入与手术选项包括子宫动脉栓塞、射频消融、高强度聚焦超声、微波消融及腺肌病病灶切除术,可缓解症状并保留子宫,但复发与生育结局未完全明确。

临床怎么用

  • 临床应结合影像学非侵入性检测识别子宫腺肌病,并注意合并肌瘤与子宫内膜异位症对症状与治疗的影响。
  • 药物选择可参考子宫内膜异位症与肌瘤证据,介入与手术可用于保留子宫的 symptom 缓解,但需告知复发与生育结局不确定性。

局限性

  • 组织学诊断缺乏共识定义,诊断仍具挑战。
  • 药物管理多外推自子宫内膜异位症与肌瘤数据。
  • 介入与手术的复发与生育结局未完全明确。
  • 需疾病特异性前瞻试验与标准化诊断标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adenomyosis is a heterogeneous, nonmalignant uterine disorder characterized by ectopic endometrium within the myometrium, leading to abnormal uterine bleeding, dysmenorrhea, chronic pelvic pain, and subfertility. Once considered a disease of multiparous women older than age 40 years, advances in imaging have expanded recognition to younger reproductive-aged patients. Pathogenesis involves sex steroid imbalance, inflammation, fibrosis, neuroangiogenesis, and stem cell-mediated mechanisms. Clinical presentation ranges from asymptomatic to severe pain and bleeding. Coexisting leiomyomas and endometriosis are common, compounding symptom severity and complicating management. Diagnosis remains challenging given a lack of consensus definitions for histologic diagnosis, although improved imaging techniques have enhanced noninvasive detection. Medical management is extrapolated largely from endometriosis and leiomyoma data, with progestins, levonorgestrel intrauterine systems, gonadotropin-releasing hormone analogs and antagonists, and emerging agents showing variable efficacy. Interventional and surgical options, including uterine artery embolization, radiofrequency ablation, high-intensity focused ultrasound, microwave ablation, and adenomyomectomy, offer symptom relief and uterine preservation, although recurrence and fertility outcomes remain incompletely defined. Adenomyosis imposes a significant burden across physical, psychologic, and socioeconomic domains. Advances in imaging, consensus regarding pathology, and novel therapies are reshaping management, underscoring the need for disease-specific prospective trials and standardized diagnostic criteria to optimize individualized, fertility-preserving care for this common, often misunderstood, condition.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Kho KA, Gingold JA, Shin JH, et al. Adenomyosis Pathophysiology, Diagnostic Advances, and Therapeutic Options. Obstet Gynecol. 2026. PMID: 41926770. doi:10.1097/AOG.0000000000006276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。